Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

5.3%

1 terminated out of 19 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (4)
P 1 (3)
P 2 (1)
P 3 (2)
P 4 (1)

Trial Status

Recruiting12
Not Yet Recruiting3
Active Not Recruiting1
Completed1
Enrolling By Invitation1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT07555210Not ApplicableRecruiting

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

NCT04981119Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT06026410Phase 1Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

NCT07117227RecruitingPrimary

Validation of RCC Predicting Model With Emulated-target Trial

NCT07234656Recruiting

Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer

NCT07197580Phase 3Recruiting

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

NCT07485114RecruitingPrimary

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07004426CompletedPrimary

Symptomatic and Incidental RCC Detection

NCT07351266Not Yet RecruitingPrimary

Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors

NCT06726421Phase 3RecruitingPrimary

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

NCT07321197Not ApplicableNot Yet RecruitingPrimary

Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Randomized Clinical Trial

NCT07171190Not ApplicableRecruitingPrimary

Targeted Abdominal CT in Conjunction With Lung Cancer Screening

NCT06818305Phase 2TerminatedPrimary

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

NCT07028125Phase 4RecruitingPrimary

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

NCT07118813RecruitingPrimary

Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment

NCT07062549Phase 1RecruitingPrimary

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

NCT06885424Enrolling By Invitation

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

NCT06960174Not ApplicableNot Yet RecruitingPrimary

Virtual Renality: Assessing the Impact of Virtual Reality on Preoperative Planning in Renal Cancer Surgery

NCT05128487Phase 1Active Not Recruiting

A Study of NDI 1150-101 in Patients With Solid Tumors

Showing all 19 trials

Research Network

Activity Timeline